Aug 29 (Reuters) - Resverlogix Corp
* under CANTOS trial treatment with Resverlogix' apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent
Aug 29 (Reuters) - Resverlogix Corp
* under CANTOS trial treatment with Resverlogix' apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent